We postulate that HER2-directed immunotherapeutic strategies may have beneficial effects in patients with ovarian carcinoma, including many of those who are negative according to routinely applied immunohistochemistry on tumors resected at primary surgery. Here, ERBB2 is linked to ovarian carcinoma.